Compare CERS & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CERS | EOD |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Investment Managers |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 252.4M |
| IPO Year | 1997 | N/A |
| Metric | CERS | EOD |
|---|---|---|
| Price | $2.49 | $6.04 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 118.1K |
| Earning Date | 02-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $199,191,000.00 | N/A |
| Revenue This Year | $25.31 | N/A |
| Revenue Next Year | $9.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.12 | $3.73 |
| 52 Week High | $2.96 | $4.71 |
| Indicator | CERS | EOD |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 61.61 |
| Support Level | $2.44 | $5.96 |
| Resistance Level | $2.74 | $6.01 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 51.76 | 88.24 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.